Inulin for Infections in the Intensive Care Unit (COVID-19)
Inulin in the Intensive Care Unit (ICU) (COVID-19)
Sponsor: Department of Defense
Enrolling: Male and Female Patients
IRB Number: AAAS2576C
U.S. Govt. ID: NCT03865706
Contact: Elissa Lynch: 212-304-5737 /
Additional Study Information: Bacterial infections often follow viral illnesses. This research tests whether inulin, a fiber supplement made from chicory root, encourages the growth of good bacteria to prevent infections following COVID-19. This study is being done to test inulin as an investigational new drug (not FDA approved) to prevent bacterial infections after COVID-19. We do not believe that inulin directly treats COVID-19. Instead, the hope is that inulin will prevent a secondary infection, which is often the cause of death in patients with COVID-19. Patients are randomized so that 2 out of 3 patients get the drug but no one knows who will get the drug and who will not. If you choose to participate, you will receive either inulin 32 g/day, inulin 16 g/day, or placebo. A placebo is a liquid or pill that contains no medicine. The inulin or placebo comes as a drink the size of a can of soda that you will drink twice daily. Two thirds of the patients get inulin and 1/3 of the patients get placebo. No one, including you and the medical team, will know whether you are getting inulin or placebo.
This study is closed
Daniel Freedberg, MD, MS
Do You Qualify?
Is the patient 18 years of age or older? Yes No
Has the patient been newly hospitalized in the ICU (within the past 72 hours)? Yes No
Has the patient tested positive for COVID-19? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Elissa Lynch